In a patient with chronic kidney disease stage 3a (eGFR ≈56 mL/min/1.73 m²), what is the significance of a hemoglobin of 16.9 g/dL, hematocrit of 52.6 %, and red‑cell distribution width of 15.5 %?

Elevated Hemoglobin and Hematocrit in CKD Stage 3a: Paradoxical Finding Requiring Evaluation for Secondary Polycythemia

These laboratory values are paradoxically elevated for a patient with CKD stage 3a and warrant immediate investigation for secondary causes of erythrocytosis, not anemia management. The hemoglobin of 16.9 g/dL and hematocrit of 52.6% are substantially higher than expected for this level of kidney function and exceed normal ranges, while the elevated RDW of 15.5% suggests underlying pathology.

Why These Values Are Abnormal

In CKD stage 3a (eGFR ≈56 mL/min/1.73 m²), you would typically expect hemoglobin levels to be lower than normal or at the lower end of normal range. Research demonstrates that mean hemoglobin levels in patients with eGFR 50-59 mL/min/1.73 m² are approximately 13.36 g/dL in women and 15.60 g/dL in men 1. Your patient's hemoglobin of 16.9 g/dL significantly exceeds these expected values.

The KDOQI guidelines establish that anemia becomes increasingly prevalent as GFR declines below 60 mL/min/1.73 m², with mean hemoglobin levels decreasing consistently at this threshold 2. This patient demonstrates the opposite pattern—polycythemia rather than anemia.

Clinical Significance of the Elevated RDW

The RDW of 15.5% is elevated (normal range typically 11.5-14.5%) and carries important prognostic implications:

• Elevated RDW independently predicts cardiovascular disease, endothelial dysfunction, and mortality in CKD patients 3, 4, 5
• RDW correlates with inflammation (CRP), oxidative stress, impaired calcification defense (lower T50), and increased carotid intima-media thickness 3, 4
• In CKD patients, RDW typically increases progressively from 13.1% in early stages to 16.0% in stage 5 5
• The combination of elevated hemoglobin with elevated RDW is particularly unusual and suggests a mixed pathology—possible polycythemia with concurrent inflammation, iron dysregulation, or ineffective erythropoiesis 4

Differential Diagnosis to Pursue

Immediate workup should focus on:

1. Secondary polycythemia causes:

   • Chronic hypoxemia (COPD, sleep apnea, high altitude, smoking)
   • Renal pathology causing inappropriate erythropoietin production (renal cysts, renal artery stenosis, renal tumors)
   • Other EPO-secreting tumors (hepatocellular carcinoma, cerebellar hemangioblastoma)
   • Testosterone therapy or anabolic steroid use

2. Cardiorenal risk factors:

   • Research shows that hemoglobin levels are paradoxically higher in CKD patients with hypertension, diabetes, and metabolic syndrome components 1
   • Assess for uncontrolled hypertension and diabetes, which correlate with higher hemoglobin at each eGFR level 1

3. Inflammatory and nutritional status:

   • Check CRP, ferritin, iron studies, vitamin B12, folate
   • The elevated RDW suggests possible concurrent iron deficiency, inflammation, or mixed nutritional deficiencies despite the high hemoglobin 4, 5

Recommended Diagnostic Approach

Order the following tests:

• Serum erythropoietin level (should be inappropriately normal or elevated given the polycythemia)
• Arterial blood gas to assess for chronic hypoxemia
• Renal ultrasound to evaluate for cysts, masses, or structural abnormalities
• JAK2 V617F mutation (to exclude polycythemia vera, though less likely with normal kidney function)
• Complete iron panel, ferritin, CRP, albumin
• Sleep study if clinical suspicion for sleep apnea
• Review medications (testosterone, erythropoiesis-stimulating agents)

Clinical Implications and Monitoring

This patient requires close cardiovascular monitoring because:

• Elevated hematocrit >52% increases blood viscosity and thrombotic risk
• The elevated RDW independently predicts endothelial dysfunction (lower flow-mediated dilation), increased carotid intima-media thickness, and cardiovascular events in CKD 4
• RDW is an independent predictor of CKD progression and mortality 5, 6

Common pitfall to avoid: Do not assume these values represent "good" kidney function or adequate erythropoietin production. The paradoxically elevated hemoglobin in the setting of CKD stage 3a is abnormal and requires explanation. Research clearly shows that at eGFR 50-60 mL/min/1.73 m², hemoglobin should be declining, not elevated 2, 1, 7.

The elevated RDW adds another layer of concern, as it reflects underlying inflammation, oxidative stress, and cardiovascular risk that is independent of the hemoglobin level itself 3, 4, 5.